Table 2.
Inhibition of miRNA combat chemoresistance by regulating autophagy.
| miRNA | Effect on autophagy | Cancer type | Resistant to | Targets | Ref |
|---|---|---|---|---|---|
| miR-1301 | Inhibition | Ovarian cancer | Cisplatin | ATG5 and Beclin1 | (184) |
| miR-487b-5p | Lung cancer | Temozolomide | LAMP2 | (185) | |
| miR-155 | Osteosarcoma | Adriamycin | PTEN | (192) | |
| miR-221/222 | Multiple myeloma | Dexamethasone | ATG12 | (186) | |
| miR-3127-5p | NSCLC | Cisplatin | STAT3 | (194) | |
| miR-15a-5p | Acute myeloid leukemia | Daunorubicin | ATG9a, ATG14, GABARAPL1, SMPD1 | (187) | |
| miR-21 | Inhibition | Breast cancer | Tamoxifen, Fulvestrant | PTEN | (188) |
| HCC | Sorafenib | PTEN/AKT | (191) | ||
| Gastric cancer | Cisplatin | PI3K/AKT/mTOR | (190) | ||
| Leukemia | Etoposide, Doxorubicin | Bcl-2 | (193) | ||
| Promotion | Colorectal cancer | Topoisomerase | proteasome pathway | (195) | |
| miR-138 | Promotion | Glioblastoma | Temozolomide | BIM | (196) |
| miR-140-5p | Osteosarcoma | Doxorubicincisplatin | IP3K2 | (197) | |
| miR-155 | Doxorubicincisplatin | (198) | |||
| miR-338-3p | p53 mutant colon cancer | 5-Fu | mTOR | (199) | |
| miR-7-5p | Cervical cancer | Cisplatin | PARP-1, Bcl-2 | (200) | |
| miR-223 | NSCLC | Cisplatin | FBXW7 | (201) |